<p>A Review on the Role of Denosumab in Fracture Prevention</p>

Abstract

Denosumab is a receptor activator of nuclear factor kappa-Β ligand inhibitor, which suppresses the bone resorption process to preserve bone mass. It is usually recommended to postmenopausal women and men with high fracture risk. With the recent publication of the results from FREEDOM study and its extension, the long-term effect of denosumab in preventing fragility fractures has been put forward. This review aims at summarising the evidence of denosumab in reducing fracture risk and its safety derived from clinical studies. Most of the evidence are derived from FREEDOM trials up to 10 years of exposure. Denosumab is reported to prevent vertebral and non-vertebral fractures. It is also proven effective in Japanese women, patients with chronic kidney diseases and breast cancer patients receiving antineoplastic therapy. Denosumab discontinuation leads to high remodeling, loss of bone mineral density and increased fracture risk. These negative effects might be preventable by bisphosphonate treatment. The safety profile of denosumab is consistent with increased years of exposure. In conclusion, denosumab is a safe and effective option for reducing fracture risk among patients with osteoporosis.

Case Report: Severe Osteoporosis and Preventive Therapy in RNA Polymerase III-Related Leukodystrophy

“…As for the treatment of osteoporosis, denosumab is an anti-RANKL monoclonal antibody that is used as a bone resorption inhibitor to treat osteoporosis (18). After the administration of denosumab, the level of bone resorption markers decreases in a short time, and improvement of bone metabolism is generally observed (19). Actually, our patient demonstrated the restoration of bone density together with the recovery in bone resorption markers and has shown no further recurrences of pathological fracture.…”

Association of Thiazide Use in Patients with Hypertension with Overall Fracture Risk: A Population-Based Cohort Study

“…The cumulative mortality rate for 12 months was 33%, and the 1-year mortality rate increased significantly by 2% per year [ 26 ] Several cost-effective pharmacologic treatments may be used to prevent fractures, such as vitamin D and calcium supplements and bisphosphonates [ 27 ]. Denosumab is an effective option for preventing fracture, which reduces bone resorption to achieve bone mass preservation [ 28 ].…”

The effectiveness of denosumab in the treatment of postmenopausal osteoporosis: 3 years of experience in a rehabilitation center

“…Unlike bisphosphonates, denosumab is not incorporated into the bone, so its effect on bone turnover markers, BMD, and This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as: Aras B, Kuzu Ö. histomorphometric measurements is reversible (9)(10)(11). In a previous study, it was shown that iliac bone biopsies performed in patients using denosumab had no adverse effects on bone mineralization, lamellar bone formation and bone microarchitecture (12).…”